New study aims to make anesthesia safer for seniors

NCT ID NCT07301242

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study at Shanghai Geriatric Medical Center looks at how the anesthetic drug ciprofol behaves in 50 older adults (65+) undergoing limb surgery. Researchers will collect blood samples and monitor vital signs to build a model that could help doctors adjust doses more precisely. The goal is to improve safety and recovery for elderly patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ciprofol (an intravenous anesthetic)

What this could lead to

If successful, this could help doctors give more precise and safer doses of ciprofol to older patients during surgery.

What could go wrong

This is a small, early observational study with only 50 participants, so results may not apply to all older adults. It is not testing a new treatment, just gathering data.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FEMORAL NECK FRACTURES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

femoral neck fracture hip fracture osteoarthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Geriatric Medical Center

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••